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Abstract
Introduction. Tissue biopsy is the gold standard for cancer diagnosis, targeted treatment, and prognosis. However, a biopsy is an invasive procedure that could result in
postoperative bleeding, pain, and infection. Such limitations may now be resolved by the clinical technique known as liquid biopsy, which enables a better representation
of disease status.
Method. This literature review was conducted through online databases (PubMed, Ascopubs, EuroPMC) using the following keywords: "liquid biopsy", "ctDNA",
"CTC", "breast cancer", "pathogenesis of breast cancer", "tumor microenvironment”, “ctdna detection technologies”, "early diagnosis", "targeted therapy" ,"monitoring
disease progression”, and "prognosis”. The literature search was conducted using the PRISMA format (Figure 1). The appraised articles were further evaluated using the
Joanna Briggs Institute (JBI).
Discussion. Liquid biopsy, also known as blood-based analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), has become more significant in
breast cancer in recent years. There are several techniques for CTC and ctDNA detection that are continuously developing. PCR-based techniques are the initial
approaches used to identify ctDNA. However, targeted deep sequencing is now superior. Instead of a tumor biopsy, a liquid biopsy might be beneficial for breast cancer
diagnosis, therapy, and prognosis based on clinical trials. However, more clinical trial studies are still needed.
Conclusion. The advancement of technology has made genetic alteration detection via liquid biopsy feasible to detect genetic alterations that are very important not only
for early detection of breast cancer but also targeted therapy and disease monitoring. Numerous studies have shown the potential of liquid biopsy as an alternative to tumor
biopsy.
Keyword: breast cancer, ctDNA, CTC, liquid biopsy

Introduction
The World Health Organization reported that in 2021 breast cancer was
the most prevalent cancer, contributing to 12% of all new cancer cases
each year.1 Studies showed that breast cancer is a multifactorial disease,
and its etiology is often unclear. However, it has been demonstrated that
genetic and environmental factors are the primary causes. In addition,
early detection and treatment can significantly increase the chances of
survival and recovery.2

detection technologies", "early diagnosis", "targeted therapy",
"monitoring disease progression" and "prognosis." These include (1)
meta–analysis, systematic review, literature review, randomized
controlled trial, clinical trials, or cohort study; (2) the subject is breast
cancer that was assessed with liquid biopsy; (3) no limitation of
publication year. In addition, the studies included in this review will be
presented in a narrative format on the potential application of the liquid
biopsy chapter.
Pathogenesis of breast cancer

Tissue biopsy is the gold standard for cancer diagnosis, molecular
analysis, and prognosis. However, it is an invasive procedure that could
result in postoperative bleeding, pain, and infection.1,2 As biotechnology
advanced along with the development of research in breast cancer
biology, liquid biopsy has gradually turned into a promising minimally
invasive tool focused on the analysis of circulating tumor cells (CTC)
and cell–free circulating tumor DNA (ctDNA) of the plasma. The
proportion of cell–free circulating DNA derived from tumor tissue is
called circulating tumor DNA (ctDNA). Identification and
measurement of ctDNA is the potential to detect the early stage of breast
cancer, identify genomic mutation for personalized therapies, prediction
of prognosis, minimal residual disease (MRD), serial sampling of
disease progression, and therapy efficacy.1 In addition, without the
requirement for a further tumor biopsy, circulating tumor DNA
(ctDNA) may offer a current evaluation of the genetic profile of
advanced cancer.2 In this review, we discuss a variety of tumor
components applied in liquid biopsy that are already applied in clinical
practice and are under investigation.
This review is based on sixteen eligible articles found in online
databases, i.e., PubMed, Ascopubs, and EuroPMC, using the following
keywords: "liquid biopsy", "ctDNA", "CTC", "breast cancer,"
"pathogenesis of breast cancer," "tumor microenvironment”, "ctdna

Breast cancer is a complex process of cancer cells growing by
progressive development through stages, commencing with epithelial
hyperproliferation and advancing to in situ, invasive, and metastatic
carcinomas.3 Recent research has demonstrated that breast cancer
comprises neoplastic cells and significantly alters the surrounding
stroma or tumor microenvironment. Cancer cells in host tissues undergo
significant genetic, cellular, and physical alterations to sustain tumor
development and progression. One of the factors that influence the steps
of cancer progression is the tumor microenvironment.4 The tumor
microenvironment comprises immune cells, stromal cells, blood vessels,
and an extracellular matrix. Engaging in a low–oxygen and acidic
environment, the tumor microenvironment promotes angiogenesis to
gain oxygen and remove metabolic waste. Various studies have
identified that the tumor microenvironment is a key factor in cancer
development, progression, and response to treatment.3,4 In selecting the
most effective therapy and monitoring disease progression, a cancer
diagnosis has revolutionized over the past decade.3 Detecting and
analyzing genomic alterations in cancer cells has led to improved
prognosis prediction and treatment and the development of novel
targeted therapies.4 However, gaining information on tumor
microenvironment (TME) characteristics needs biopsy and resection
specimens which are invasive. The limitations of current diagnostic tools
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have delayed technique development for decades.4,5 Nowadays,
personalized medicine and genetic profiling using liquid biopsy have
recently emerged as less invasive tools for therapeutic, diagnosing, and
monitoring breast cancer progression.5
Components in liquid biopsy
Liquid biopsy is a minimally invasive method for diagnosing a patient's
illness and is a crucial technique for assessing cancer progression.6
Nucleic acid, extracellular vesicles, proteins, or other biological
components released into body fluids by cancer cells are the compounds
of liquid biopsies. According to the findings of several research studies,
among all the analytes, CTC and ctDNA are potential biomarkers in
breast cancer.6,7 In this review, we will focus on detecting plasma CTC
and ctDNA.
Circulating nucleic acids (CTCs)
CTCs are primary or metastatic tumor cells that are released into
circulation. Through epithelial–to–mesenchymal transition (EMT),
these cells can adapt and survive in the bloodstream and may contribute
to metastasis. The precise process responsible for their release remains
unknown.7 CTCs have a nucleus, are positive for cytokeratins, are
identified by the antibodies C11 and A53–B/A2, do not stain for CD45,
are larger than 4 x 4 m, and have a cell–like shape. CTCs have a short
peripheral circulatory system with a half–life of approximately 1 to 2.4
hours.8,9 Active clearance of CTCs from the circulation or extravasation
to secondary organs that contribute to metastasis. Thus, clusters of CTCs
are associated with tremendous metastatic potential and a worse
prognosis.9
Various studies have shown the ability to identify CTCs using
immunologic, molecular, or functional techniques. Epithelial markers
such as epithelial cell adhesion molecule (EPCAM) and cytokeratins are
used to detect CTC. In contrast, the epithelial tumor may go through
epithelial–to–mesenchymal transition (EMT), which reduces the
expression of epithelial markers. Thus, several researchers are
developing novel approaches for detecting CTC undergoing EMT.10
Cristofanilli et al. conducted the first seminal study on the prognostic
significance of CTC level in 2004 utilizing a highly automated
immunomagnetic CTC screening technology called CellSearch. A
threshold of > 5 CTC/7.5 mL measured at baseline and a few weeks after
therapy was associated with short progression–free survival (PFS),
which was linked with a poor prognosis. This study showed that the
detection of CTC level in plasma outperformed plasma CEA and
CA.15.3 in terms of accuracy. Multiple studies have demonstrated that
CTC can accurately assess therapy effectiveness, early diagnosis,
metastatic progression, recurrence, and prognosis.11
Cell–free DNA (cf–DNA)/circulating tumor DNA (ctDNA)
Cell–free DNA (cfDNA) consists of DNA from the normal host cells
and circulating tumor DNA (ct–DNA). Normal host cells consistently
produce fewer than 200 base pairs in length DNA fragments but
circulating tumor cells have longer DNA fragments that can reach
several kilobases. In cancer patients, tumor cells produce the majority of
cfDNA, referred to as ctDNA. Depending on tumor size, location,
vascularization, therapy, and clearance, the fraction of ctDNA ranges
from 0.05% to 90%.12 ctDNA is the double or single–stranded
fragmented DNA released into body fluids by tumor–specific genetic
alterations released from primary tumors, CTCs, micrometastasis, or
metastatic tumors in cancer patients.13 Tumor cells have the same
inherent potential to shed DNA as normal cells but with larger quantities
due to higher cellular turnover. cfDNA levels vary from 13 ng/mL in
healthy people to 180 ng/mL in advanced malignancies.14 Once ctDNA

is detected in circulation, it is feasible to analyze these fragments' genetic
and epigenetic profiles to identify specific cancer mutations generated
by tumor cells. ctDNA is eliminated by the liver, spleen, and kidneys
between 30 and 4 hours, enabling a real–time evaluation of tumor
burden.13,14 In addition, ctDNA may be transferred by other cells in the
body and contribute to the genometastasis that occurs in cancer
patients.13
Technologies for ctDNA analysis
PCR–based methods
Quantitative real–time PCR has been used to measure the amount of
specific ctDNA fragments. However, traditional PCR–based liquid
biopsy techniques have limited sensitivity to detect low mutant allele
concentrations. Due to the limitation of conventional PCR, the
researchers have developed the last generation of PCR, digital PCR
(ddPCR), with higher sensitivity.15 Other methods for quantifying
ctDNA that are PCR based are BEAMing (Beads, Emulsion,
Amplification, and Magnetics). BEAMing could use ctDNA to identify
mutations in the PIK3CA gene. In addition, ctDNA may also assess
epigenetic modifications such as promoter or enhancer methylation.15,16
Methylation–specific PCR (MS–PCR) is one of the most frequent
gene–specific DNA methylation detection methods. The detection of
methylated CpG sites starts with bisulfite conversion. Methylated
sequences are amplified using methylation–specific primers after the
conversion.16
Targeted deep sequencing
Using next–generation sequencing (NGS) and a combination of PCR
and NGS, targeted deep sequencing has been used to identify particular
genomic regions or novel somatic mutations. However, the sensitivity
of NGS for identifying targeted ctDNA mutations is highly sensitive.
Therefore, tagged–Amplicon deep sequencing (TAm–seq), Safe–
Sequencing System (Safe–SeqS), Cancer Personalized Profiling by
deep sequencing (CAPP–Seq), and Ion Torrent were developed for
applying NGS to target panels.21,25
Table 1. Various techniques using the platform to detect alterations and their
targets
Technology

Platform
qPCR
ddPCR

PCR–based
methods

BEAMing
MS–PR
ARMS
TAm–seq

Safe–SeqS
Targeted deep
sequencing

Type of alteration
Known
point
mutation
Known
point
mutation
Known
point
mutation
Known
mutation

point

Known
mutation
Known
mutation

point
point

Known
point
mutation and copy
number variations

Target
Rearrangements
Rearrangements,
PIK3CA mutations
PIK3CA mutations
Gene–specific
detection of specific
cpG islands
Hotspot PIK3CA
mutations, SNPs
SNVs

SNVs

Known
point
Rearrangements
mutation,
copy
number variations,
and rearrangements
Somatic
variant
Ion Torrent
Selected SNVs
detection
qPCR: Quantitative polymerase chain reaction; ddPCR: Droplet digital polymerase chain
reaction; BEAMing: Beads, emulsion, amplification, magnetics; MS–PCR:
Methylation–specific polymerase chain reaction; Safe–SeqS: Safe–sequencing system;
CAPP–Seq: Cancer personalized profiling by deep sequencing; SNV: Single–nucleotide
variant
CAPP–Seq
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Epigenetic DNA alterations
Bisulfite conversion–based methods
DNA methylation occurs early in carcinogenesis; hence, methylation
ctDNA biomarkers have been analyzed in various tumor types. As a
biomarker, methylation DNA has the advantage of not requiring the
presence of particular mutations. In cancer patients, CpG islands that are
typically unmethylated may have become methylated, resulting in gene
repression.17 Early DNA methylation research focused on the
hypermethylation of CpG islands of important driver genes, such as
estrogen receptors and BRCA1. A potential biomarker for early breast
cancer identification has been plasma–circulating cfDNA methylation
status.18 The gold standard for DNA methylation study is bisulfite
conversion–based methods. There are some bisulfite conversion–based
methods such as whole–genome bisulfite sequencing (WGBS),
Reduced–Representation Bisulfite Sequencing (RRBS), Methylation–
specific PCR (MSP), Methylated CpG Tandems Amplification and
Sequencing (MCTA–seq), Targeted Bisulfite Sequencing. The most
comprehensive and reliable DNA methylation profiling technique is
WGBS. WGBS can detect the methylation status of each cytosine,
particularly low CpG density areas and non–CpG sites (CpA, CpT, and
CpC).17,18 However, the disadvantage of WGBS is its extremely high
cost. Until now, no individual sample analysis has been performed due
to the high cost of large–scale WGBS17–19 RBS was developed by
combining MspI digestion, bisulfite conversion, and NGS to analyze
CpG–rich regions. Widschwendter et al. discovered that blood DNA
methylation indicators using RRBS might predict breast cancer
mortality up to one year after diagnosis.19 Unfortunately, since RRBS
requires a high amount of cfDNA, it is unsuitable to be applied,
particularly in early–stage breast cancer. A solution to this issue is that
DNA damage may be prevented by single–cell RRBS (scRRBS).18,19
Other methods are methylation–specific PCR (MSP) which is the most
common technique for gene–specific detection, methylated CpG
Tandems Amplification and Sequencing (MCTA–seq), which is
effective detection of hepatocellular carcinoma (HCC), and colorectal
cancer.17,18 The last technique is targeted bisulfite sequencing, which
is not practicable for clinical applications since the primer and probe
designs for bisulfite–converted sites are pretty complex.17
Potential application of liquid biopsy
Liquid biopsy has some advantages and disadvantages compared to
tumor biopsy. Tumor biopsy is invasive; obtaining the sample in certain
tumors is sometimes challenging. On the other hand, liquid biopsy only
requires a simple blood sample to obtain several tumor materials like
circulating tumor cells (CTC) and circulating–free DNA (cfDNA),
which are needed for analysis.2 In addition, not all patients are eligible
for tumor biopsy; for example, to perform breast core biopsy, there are
several relative contraindications: consuming anticoagulant, pregnancy,
lactation, and the patient's clinical condition. Compared to tumor biopsy,
liquid biopsy does not have specific contraindications and is eligible for
all patients.9
Whole genome amplification (WGA) is a technique to analyze cancer
heterogeneity mutation in CTC. The advantages of using WGA are that
it is superior to detecting heterogeneity compared to cell–free DNA or
exosome. For example, in breast cancer, PIK3CA mutations detected in
CTC with WGA are linked with poor diagnosis. In addition, both
collection of tumor samples and liquid biopsy can do RNA profiling
except for cfDNA.13 CTC is a cell shed from a primary or metastatic
tumor containing DNA and RNA. Meanwhile, cfDNA are degraded
DNA fragments (including ctDNA) with no RNA fragment. As a result,
RNA profiling from cfdna is not achievable. Nevertheless, RNA

profiling provides reliable indicators for disease status, implying that it
could be used for early diagnosis and disease classification.19
The clinical application of tumor biopsy is more widely used in daily
practice since tumor biopsy remains the gold standard for cancer
diagnosis.14 However, due to the expansion of liquid biopsy research,
oncologists have started to utilize liquid biopsy as early cancer detection,
treatment follow–up, and determining prognosis. On the other hand, the
study of liquid biopsy may enhance genetic analyses of tumor
heterogeneity and clonal evolution in solid tumors. In addition,
identifying circulating biomarkers in liquid biopsy is effective,
enhancing personalized medicine.11

Figure 1. Benefits of liquid biopsy to tumor biopsy

Early diagnosis of breast cancer
Circulating tumor DNA (ctDNA) provides a new generation of early
breast cancer diagnostic tools. However, plasma ctDNA levels are
assumed to be low in early–stage breast cancer due to the low tumor
burden. A study of 640 cancer patients revealed that individuals with
stage 4 disease had a 100–fold increase in median ctDNA concentration
compared to those with stage 1. As a result of the low level of ctDNA in
plasma, early detection of breast cancer with ctDNA is quite
challenging, requiring highly sophisticated detection and quantification
methods.20 Aside from detecting ctDNA levels, genetic alteration can
also be observed. Multiple technologies have been employed to detect
ctDNA that are continuously being developed. The first popular method
to detect plasma DNA mutations is digital–PCR (dPCR). However,
dPCR has several limitations, including the inability to detect new
mutations that have not yet been identified.6 Tumor protein p53 (TP53)
and phosphatidylinositol–4,5–bisphosphate 3–kinase catalytic subunit
alpha (PIK3CA) are frequently mutated genes in primary breast cancer,
according to Cancer Genome Atlas (TCGA).21 A prospective study by
Beaver et al. showed that ctDNA could detect PIK3CA mutation with
the ddPCR technique during the early stage of breast cancer plasma
before and after surgery.22 Analysis for mutations in tumor tissues led to
93% concordant detection of those mutations in presurgical plasma
samples. The potential of ctDNA in patients in the early stage was
established by the high sensitivity (93.3%) and specificity (100%) using
ddPCR. Another technique recently emerging as a novel instrument for
enhancing the sensitivity of massively parallel sequencing systems for
identifying rare variants in plasma DNA is a new targeted next–
generation sequencing (NGS) like SafeSEQ.15 A study designed by
Rodriguez et al. showed that ctDNA analysis using SafeSEQ (Sysmex
Inostics) technology and an NGS Truseq custom low input panel might
be used as an alternative to tissue biopsy (Illumina). Based on the study,
ctDNA sequencing could identify additional TP53 and PIK3CA
mutations which were not detected in tumor biopsy sequencing (21).
37

The New Ropanasuri Journal of Surgery 2022 Volume 7 No. 2: Page 35–40

Another study found that 71% of patients with early–stage breast cancer
had somatic mutations in the plasma using targeted error correction
sequencing (TEC–seq) for identifying genetic abnormalities in
ctDNA.23
Table 2. Clinical trials using ctDNA as an early diagnosis in breast cancer
Authors
(Reference)

Type of
Study

Beaver et al.
(22)

Prospective
Study

Rodriguez
et al. (21)

Pilot Study

Phallen et
al. (23)

Cohort

Number
of
Patients

Techniques

Mutation
Detected

30
patients

ddPCR

PIK3CA

The potential of
ctDNA in patients
with early–stage
breast cancer was
demonstrated by the
high
specificity
(100%)
and
sensitivity (93.3%)
of ddPCR.

29
patients

NGS

TP3 and
PIK3CA

PIK3CA mutations
were discovered in
the tumor biopsies
of 79.3% (23/29)
and 34.5% (10/29)
of the patients with
early breast cancer,
respectively. At the
same time, a plasma
sample showed the
same alterations in
34% of 10/29 of the
patients.

200
patients
(Multiple
tumor
types)

TEC–Seq

Not
specified

Result

ctDNA was found
in 56% of stage I–III
breast
cancer
patients.

Targeted Therapy
Mutations in tumor–related genes have led to important advances in
cancer biology and the development of precision medicine. Early
intervention in breast cancer patients may be advantageous by detecting
CTCs and/or ctDNA. However, enumeration of CTC level is not often
associated with metastatic breast cancer prognosis, especially in ER–
positive breast cancer. At the same time, tumors are not always
susceptible to endocrine therapy due to ER–negative CTCs resistant to
the treatment. As a result, A CTC–Endocrine Therapy Index (CTC–
ETI) was developed based on CTC quantification and the expression of
estrogen receptors, BCL–2, HER2, and Ki67.24 A study by Bidard et al.
regarding CTC–driven selection therapy was randomly done in 764
metastatic breast cancer patients. Three hundred eighty–seven patients
were treated according to clinicians–driven treatment options, while
another 377 patients were treated with CTC–driven treatment options.
Driven by the CTC, patients will receive either endocrine therapy or
chemotherapy depending on the quantity of CTC: chemotherapy if CTC
is high or endocrine therapy if CTC is low. Targeted therapy is
particularly challenging in metastatic breast cancer due to unfeasible
sites, especially when metastasis has untypical localization.25 In addition
to CTC, a phase 2a multi–cohort research discovered the potential use
of ctDNA for targeted treatment. The samples were collected from
patients who had received minimal one prior treatment for metastatic
breast cancer or patients who relapsed within a year after receiving
neoadjuvant or adjuvant chemotherapy. The patients were enrolled in
one of four treatment cohorts based on their ctDNA mutation status:
cohort A included those with ESR1 mutations who were given
intramuscular extended–dose fulvestrant 500 mg; cohort B included
those with HER2 mutations who were given oral neratinib 240 mg and
estrogen receptor–positive, intramuscular standard–dose fulvestrant;

and cohort C had those with AKT1 mutations and estrogen receptor
which were treated with oral capivasertib 480 mg. The findings
demonstrated that ctDNA detection is highly reliable, with excellent
agreement between different ctDNA investigating methods and high
sensitivity for mutations found in advanced breast cancer tissue biopsies.
Additionally, ctDNA detection offers rapid genotyping that enables
patients with breast cancer to determine mutation–directed therapy.26
Monitoring disease progression
Monitoring CTCs and ctDNA during cancer therapy can be less
challenging than early detection of breast cancer. Liquid biopsies enable
continuous sampling during the treatment. The non–invasive and
dynamic properties may provide patients with a real–time indicator of
the efficacy of the adjuvant treatment. It has been shown that monitoring
disease relapse while receiving treatment significantly involves ctDNA
and CTCs.27 In a study by Rack et al., CTCs levels were compared
before and after neoadjuvant chemotherapy. Before treatment, CTCs
were found in 21.5% of patients, despite the tumor's size, grade, or
hormone receptor status. After chemotherapy, 22.1% of patients were
CTC–positive. Poor disease–free survival was associated with the
presence of CTCs.28
In addition to monitoring treatment, early diagnosis of relapse after a
complete primary breast cancer resection is also a priority for
oncologists. Currently, laboratory evaluations and routine
mammography are still advised for follow–up. Therefore, rapid
innovations in sequencing technology and ctDNA analysis have made
it potential to be monitored during follow–up. A study by McDonald et
al. showed that the detection of ctDNA mutations consistently in two to
four weeks after surgery was associated with a high risk of early relapse.
Detection of ctDNA mutations has some benefits, including delivering
precise or targeted therapy while keeping track of the disease
progression, resistance to treatment, and relapse.29 Another prospective
cohort study demonstrates that monitoring ctDNA during treatment can
predict cancer progression 4–6 months earlier than the traditional
approaches. The study sample consists of 45 breast cancer patients
receiving neoadjuvant chemotherapy, endocrine treatment, or palliative
care for metastatic diseases. The plasma and tumor samples obtained
before and after treatment were analyzed to determine the mutation
status. Approximately two–thirds of patients had detectable mutations,
and there were novel pathogenic changes in the follow–up plasma that
was not present in the tumor sample or baseline plasma.30
Table 3. Clinical trials using ctDNA for monitoring disease progression in breast cancer.
Authors
(Reference)

Study Design

Techniques

Outcome

Rack et al.28

CTCs
before
and
following
adjuvant
chemotherapy

CellSearch
System

CTCs following chemotherapy is
associated with reduced disease–
free and overall survival.

McDonald
et al.29

ctDNA before, during,
and
following
neoadjuvant
chemotherapy

Targeted
Digital •
Sequencing
(TARDIS)

Priskin et
al.30

Detection of ctDNA
mutations before, during,
and after neoadjuvant
chemotherapy, endocrine
therapy, or palliative care
for metastatic illnesses.

Next
Generation
Sequencing

•

ctDNA levels reduced during
therapy
The presence of ctDNA
mutations two to four weeks after
surgery was associated with a high
risk of early relapse.
Two–thirds of the patients
exhibited detectable mutations,
and the follow–up plasma had
pathogenic changes that were not
found in the tumor sample or
baseline plasma.

Prognosis and minimal residual disease
Evidence shows that minimal residual disease (MRD) is strongly related
to disease recurrence; hence, finding particular genetic and molecular
38
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abnormalities as new minimal residual disease (MRD) detection targets
utilizing ctDNA has become a research focus. ctDNA is a feasible
biomarker as it contains genetic and epigenetic changes found in tumors.
Therefore, it has the potential for prognosis prediction in breast cancer.
Patients with early–stage breast cancer receive neoadjuvant therapy
(NAT) as a standard in clinical practice. However, evaluating and
predicting NAT response remains a significant challenge after
completing NAT. Different biochemical biomarkers, such as proteins,
enzymes, DNA, and RNA, could be used to predict breast cancer and
monitor treatments.31 Currently, CA15–3 and CEA are chemical
biomarkers that are widely utilized. However, Due to low sensitivity and
specificity, the American Society of Clinical Oncology (ASCO) stated
that CEA, CA15–3, CA27,29 lactate dehydrogenase, and others were not
recommended for screening, diagnosis, or staging of breast cancer
patients after primary therapy. In early–stage breast cancer, pathologic
complete response (pCR) following neoadjuvant therapy has been
linked to improved event–free survival (EFS) and overall survival (OS).
However, some patients with pCR experienced recurrence or metastasis,
and the absence of pCR does not necessarily correlate with recurrence.32
The innovation of circulating tumor DNA (ctDNA) has potential clinical
applications. Some studies proved that ctDNA could predict the
prognosis of the disease. A study by Lin et al. demonstrated that
identifying ctDNA after NAT has significant clinical value potential as
a predictive marker in stage II to III breast cancer patients. In the study,
95 patients were included, 60 showed ctDNA positivity before NAT,
and 31 showed ctDNA positivity after NAT. In both patients who
achieved and did not achieve pCR, the presence of ctDNA following
NAT was a substantial risk factor for recurrence.33 Another systematic
review and meta–analysis by Papakonstantinou et al. demonstrated that
identification of ctDNA at baseline and after NAT completion was
substantially linked with reduced Relapse–Free Survival (RFS).34
Moreover, the measurement of ctDNA levels is also statistically
significant for predicting disease–free survival (DFS), according to
Cullinane et al. This meta–analysis and systematic review discovered
that patients with increased ctDNA levels had shorter disease–free
survival (DFS). ctDNA was substantially related to a lower relapse–free
survival rate, suggesting that it has the potential to identify preclinical
disease recurrence in breast cancer patients following treatment.35
Conclusions
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Liquid biopsies in breast cancer have shown promising results,
particularly in early diagnosis, targeted therapy, evaluating therapy
response, and predicting disease progression or recurrence. Liquid
biopsies may play a larger role in the breast cancer clinic due to more
research and, ideally, the continuous development of technologies that
identify tumor–derived substances.
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